Biomaterial Database

Essential thrombocythemia transforming into acute biphenotypic leukemia in a patient on hydroxyurea monotherapy. 2009

G Sandhu, and A Ranade, and S Siddiqi, and J L Balderacchi

UI	MeSH Term	Description	Entries
D002471	Cell Transformation, Neoplastic	Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918	Hydroxyurea	An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.	Hydroxycarbamid,Hydrea,Oncocarbide
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly
D000970	Antineoplastic Agents	Substances that inhibit or prevent the proliferation of NEOPLASMS.	Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013920	Thrombocythemia, Essential	A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.	Hemorrhagic Thrombocythemia,Thrombocythemia, Hemorrhagic,Thrombocythemia, Idiopathic,Thrombocythemia, Primary,Primary Thrombocythemia,Thrombocytosis, Autosomal Dominant,Thrombocytosis, Primary,Autosomal Dominant Thrombocytoses,Autosomal Dominant Thrombocytosis,Dominant Thrombocytoses, Autosomal,Dominant Thrombocytosis, Autosomal,Essential Thrombocythemia,Essential Thrombocythemias,Hemorrhagic Thrombocythemias,Idiopathic Thrombocythemia,Idiopathic Thrombocythemias,Primary Thrombocythemias,Primary Thrombocytoses,Primary Thrombocytosis,Thrombocythemias, Essential,Thrombocythemias, Hemorrhagic,Thrombocythemias, Idiopathic,Thrombocythemias, Primary,Thrombocytoses, Autosomal Dominant,Thrombocytoses, Primary
D015456	Leukemia, Biphenotypic, Acute	An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.	B- and T-Cell Acute Lymphoblastic Leukemia,B- and T-Cell Leukemia, Acute,Leukemia, Lymphocytic, Acute, Mixed-Cell,Leukemia, Mixed, B- and T-Cell,Leukemia, Mixed-Cell,Lymphocytic Leukemia, Acute, B- and T-Cell,Acute Biphenotypic Leukemia,B and T Cell Acute Lymphoblastic Leukemia,B and T Cell Leukemia, Acute,Biphenotypic Acute Leukemia,Hybrid Acute Leukemias,Leukemia, Lymphocytic, Acute, Mixed Cell,Leukemia, Mixed, B and T Cell,Lymphocytic Leukemia, Acute, B and T Cell,Mixed-Lineage Acute Leukemias,Acute Biphenotypic Leukemias,Acute Leukemia, Biphenotypic,Acute Leukemia, Hybrid,Acute Leukemia, Mixed-Lineage,Acute Leukemias, Biphenotypic,Acute Leukemias, Hybrid,Acute Leukemias, Mixed-Lineage,Biphenotypic Acute Leukemias,Biphenotypic Leukemia, Acute,Biphenotypic Leukemias, Acute,Hybrid Acute Leukemia,Leukemia, Acute Biphenotypic,Leukemia, Biphenotypic Acute,Leukemia, Hybrid Acute,Leukemia, Mixed Cell,Leukemia, Mixed-Lineage Acute,Leukemias, Acute Biphenotypic,Leukemias, Biphenotypic Acute,Leukemias, Hybrid Acute,Leukemias, Mixed-Cell,Leukemias, Mixed-Lineage Acute,Mixed Lineage Acute Leukemias,Mixed-Cell Leukemia,Mixed-Cell Leukemias,Mixed-Lineage Acute Leukemia
D020521	Stroke	A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	Apoplexy,Cerebral Stroke,Cerebrovascular Accident,Cerebrovascular Apoplexy,Vascular Accident, Brain,CVA (Cerebrovascular Accident),Cerebrovascular Accident, Acute,Cerebrovascular Stroke,Stroke, Acute,Acute Cerebrovascular Accident,Acute Cerebrovascular Accidents,Acute Stroke,Acute Strokes,Apoplexy, Cerebrovascular,Brain Vascular Accident,Brain Vascular Accidents,CVAs (Cerebrovascular Accident),Cerebral Strokes,Cerebrovascular Accidents,Cerebrovascular Accidents, Acute,Cerebrovascular Strokes,Stroke, Cerebral,Stroke, Cerebrovascular,Strokes,Strokes, Acute,Strokes, Cerebral,Strokes, Cerebrovascular,Vascular Accidents, Brain